LiveSpo® Navax: PROBIOTIC THẾ HỆ MỚI HỖ TRỢ ĐIỀU TRỊ VÀ PHÒNG NGỪA VIÊM ĐƯỜNG HÔ HẤP CẤP TÍNH DO NHIỄM VIRUS

Abstract

Virus-caused Acute Respiratory Tract Infections (ARTIs) are among the most frequent diseases worldwide, with a high fatality rate. The worldwide influenza and covid-19 pandemics have had a serious impact on humanity because the viral muations develop at a rate quicker than human ability to discover, manufacture, and distribute vaccines, as well as immunization. Furthermore, the widespread use of antibiotics to treat respiratory co-infection bacteria without a doctor's prescription contributes to an increase in antibiotic resistance. In view of this situation, many scientists around the world have researched and developed probiotics, also known as beneficial bacteria, to support the treatment and prevention of ARTIs because this is a safe and potentially effective approach. Recently, LiveSpo^® Pharma successfully created LiveSpo^® Navax, a physiological saline suspension containing 5-billion beneficial Bacillus spores for ear, nose, and throat spraying administration. In this paper, we review some of the research findings including (i) clinical trials on the efficacy of LiveSpo^® Navax delivered through nasal spray in the treatment and prevention of ARTIs in children infected with RSV and influenza, and (ii) two case studies on the efficacy of LiveSpo^® Navax in the treatment of symptomatic Covid-19 infection in two families of individuals with moderate and mild symptoms.